BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35813258)

  • 1. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
    Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
    Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
    Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
    Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    Patel HD; Koehne EL; Shea SM; Fang AM; Gerena M; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
    BJU Int; 2023 Feb; 131(2):227-235. PubMed ID: 35733400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
    Falagario UG; Silecchia G; Bruno SM; Di Nauta M; Auciello M; Sanguedolce F; Milillo P; Macarini L; Selvaggio O; Carrieri G; Cormio L
    Front Oncol; 2020; 10():603384. PubMed ID: 33489907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator.
    van Riel LAMJG; Jager A; Meijer D; Postema AW; Smit RS; Vis AN; de Reijke TM; Beerlage HP; Oddens JR
    Ther Adv Urol; 2022; 14():17562872221088536. PubMed ID: 35356754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer.
    Wagaskar VG; Levy M; Ratnani P; Moody K; Garcia M; Pedraza AM; Parekh S; Pandav K; Shukla B; Prasad S; Sobotka S; Haines K; Punnen S; Wiklund P; Tewari A
    Eur Urol Open Sci; 2021 Jun; 28():9-16. PubMed ID: 34337520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
    Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
    BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
    Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
    Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
    Vedder MM; de Bekker-Grob EW; Lilja HG; Vickers AJ; van Leenders GJ; Steyerberg EW; Roobol MJ
    Eur Urol; 2014 Dec; 66(6):1109-15. PubMed ID: 25168616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
    World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Fang AM; Shumaker LA; Martin KD; Jackson JC; Fan RE; Khajir G; Patel HD; Soodana-Prakash N; Vourganti S; Filson CP; Sonn GA; Sprenkle PC; Gupta GN; Punnen S; Rais-Bahrami S
    Cancer; 2022 Sep; 128(18):3287-3296. PubMed ID: 35819253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer.
    Morote J; Borque-Fernando Á; Triquell M; Campistol M; Servian P; Abascal JM; Planas J; Méndez O; Esteban LM; Trilla E
    Eur Urol Open Sci; 2023 Jul; 53():46-54. PubMed ID: 37441350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of prostate cancer diagnosis by machine learning techniques: an algorithm development and validation study.
    Chiu PK; Shen X; Wang G; Ho CL; Leung CH; Ng CF; Choi KS; Teoh JY
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):672-676. PubMed ID: 34267331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy.
    Pallauf M; Steinkohl F; Zimmermann G; Horetzky M; Rajwa P; Pradere B; Lindner AK; Pichler R; Kunit T; Shariat SF; Lusuardi L; Drerup M
    World J Urol; 2022 Oct; 40(10):2451-2457. PubMed ID: 35941246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy.
    Chen R; Xie L; Xue W; Ye Z; Ma L; Gao X; Ren S; Wang F; Zhao L; Xu C; Sun Y;
    Urol Oncol; 2016 Sep; 34(9):416.e1-7. PubMed ID: 27185342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
    Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
    Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.